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Renal damage is more frequent with new-generation lithotripters. However, animal 31 
studies suggest that voltage ramping minimizes the risk of complications following 32 
extracorporeal shock wave lithotripsy (SWL). In the clinical setting, the optimal 33 
voltage strategy remains unclear.  34 
Objective 35 
To evaluate whether step-wise voltage ramping can protect the kidney from damage 36 
during SWL.  37 
Design, setting and participants 38 
A total of 418 patients with solitary or multiple unilateral kidney stones were 39 
randomized to receive SWL with the MODULITH® SLX-F2 lithotripter with either step-40 
wise voltage ramping (n=213) or fixed maximal voltage (n=205).  41 
Intervention: SWL. 42 
Outcomes measurements and statistical analysis: Primary outcomes were 43 
sonographic evidence of renal hematomas and levels of the urinary markers of renal 44 
damage. Secondary outcomes included stone disintegration, stone-free rate, and 45 
rates of secondary interventions within 3 months of SWL. Descriptive statistics were 46 
used to compare clinical outcomes between the two groups. Logistic regression 47 
models were generated to assess predictors of hematomas. 48 
Results and limitations 49 
Significantly fewer hematomas occurred in the “ramping” group than in the “fixed” 50 
group (12/213 (5.6%) vs 27/205 (13%), p=0.008). The “fixed” group exhibited 51 
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significantly higher urinary β2-microglobulin levels after SWL compared to the 52 
“ramping” group (p=0.02). Urinary microalbumin levels, stone disintegration, stone-53 
free rate, and rates of secondary interventions did not significantly differ between the 54 
two groups. While univariate analysis revealed a higher risk for renal hematomas in 55 
patients aged ≥70 yrs and in patients with body mass index >30 kg/m2, in 56 
multivariable analysis the mode of voltage application was the only significant 57 
predictor (OR=0.37 [95% CI:0.18-0.77] in favor of voltage ramping).The study was 58 
limited by the use of ultrasound to detect hematomas. 59 
 60 
Conclusion 61 
In this prospective, randomized study, step-wise voltage ramping during SWL was 62 
associated with lesser risk of renal damage compared to fixed maximal voltage. At 63 
the same time, treatment effectiveness was not compromised.  64 
 65 
Current controlled trials: ISRCTN95762080 66 
Patient summary: Lithotripsy is a noninvasive technique that consists of stone 67 
disintegration with ultrasonic energy. In this study, two voltage strategies are 68 
compared. The results show that progressive increase of voltage during lithotripsy 69 





Introduction in the early 1980s of the Dornier HM-3 lithotripter for extracorporeal 73 
shockwave lithotripsy (SWL) revolutionized the treatment of urolithiasis [1]. Major 74 
urological associations currently recommend SWL as first-line treatment for kidney 75 
stones <2cm located in the pelvis, or upper or middle calices [2,3]. In recent years, 76 
several new-generation lithotripters have been introduced, many of which are being 77 
used in everyday clinical practice. Although SWL is generally considered a safe 78 
procedure, it is associated with post-interventional renal hematomas in 0.5%-13% of 79 
all cases according to prospective data [4-7]. Severe hematomas can initiate an 80 
inflammatory response resulting in scar formation and damage to tubules with 81 
subsequent loss of functional renal mass [8].  82 
Against this background, current research is dedicated to improving SWL treatment 83 
strategies in order to minimize the risk of hematomas while maintaining or improving 84 
clinical effectiveness. Porcine models have shown that step-wise voltage ramping 85 
can significantly reduce the extent of renal parenchymal hemorrhagic lesions [9]. To 86 
date, clinical evidence has come only from trials with a small number of participants 87 
and/or suboptimal study design [10-12]. Notwithstanding their shortcomings, these 88 
studies suggest that voltage ramping is safe and may even confer a protective effect 89 
compared to fixed voltage treatment. On the other hand, data on the impact of 90 
voltage application on clinical effectiveness are conflicting [10-12].  91 
To redress the deficiencies of previous studies, we conducted a well-powered, 92 
single-blinded, prospective randomized trial to evaluate the effect of step-wise 93 
voltage ramping on renal damage during SWL of kidney stones.94 
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Material and Methods 95 
a) Patients and randomization 96 
From July 2010 to March 2013, a total of 418 patients (296 males and 122 females) 97 
≥16 yrs of age requiring elective or emergency SWL were randomized without 98 
stratification by a software program to treatment using the MODULITH® SLX-F2 99 
lithotripter (Storz Medical AG, Trägerwilen, Switzerland) with either step-wise voltage 100 
ramping or fixed maximal voltage (Figure 1). Unrestricted randomization was chosen 101 
because of the high number of patients to be recruited. Allocation concealment until 102 
the intervention was ensured by the use of a password-protected computer 103 
database. Inclusion criteria were solitary or multiple unilateral radiopaque kidney 104 
stones <3cm in diameter, ability to receive neuroaxial regional or general anesthesia, 105 
and written informed consent. Exclusion criteria were concurrent ureteral stone and 106 
contraindications to SWL according to standard guidelines: pregnancy, 107 
uncompensated bleeding diathesis (i.e. anticoagulation or platelet anti-aggregation 108 
therapy), and uncontrolled urinary tract infection [2,3]. Patients sent by a referring 109 
urologist explicitly to be treated with the Dornier HM-3 lithotripter were also excluded 110 
(Figure 1). The study protocol was approved by the Ethics Committee of the Canton 111 
Bern, Switzerland (protocol number 089/10). 112 
 b) Treatment protocol 113 
All patients received SWL treatment under regional of general anesthesia in order to 114 
eliminate pain as a limiting factor and to keep respiratory movements regular as it is 115 
a common practice at our department. The MODULITH® SLX-F2 lithotripter is a 116 
third generation electromagnetic lithotripter that uses both inline fluoroscopy and 117 
ultrasound to locate the stone. Only the standard focal size (6x28mm) was used for 118 
both groups. In the “ramping” group, treatment started with a series of 500 SWs at 119 
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level 7 corresponding to 14 kV) followed by 1000 SWs at level 8 (16 kV) and 1000 120 
SWs at level 9 (18 kV). In the “fixed” group, 2500 SWs at level 9 were administered. 121 
In both groups treatment was terminated prior to reaching the maximum number of 122 
SWs upon documentation of complete fragmentation on x-ray. Shock wave delivery 123 
rate was heart beat triggered [6]. Every SWL treatment was performed by the 124 
same technician with more than 25 years of experience, under the supervision and 125 
guidance of a specially-trained resident and senior staff member.  126 
c) Follow up 127 
Patients were followed up one day and 3 months after SWL using ultrasound to 128 
evaluate the presence of subcapsular or perirenal hematoma, and by kidney, ureter 129 
and bladder (KUB) x-ray to categorize the degree of stone disintegration: stone-free, 130 
fragments <2mm, fragments 2–5mm, or fragments >5mm. All radiographic images 131 
were evaluated by the same blinded reader to minimize interobserver variability. If 132 
the patient was classified as stone-free according to KUB x-ray one day after SWL, 133 
no further imaging was performed at 3 month follow up. Complications and 134 
secondary interventions were prospectively assessed by a blinded study nurse. Urine 135 
samples were obtained before and 24 hours after SWL and analyzed for tubular (β2-136 
microglobulin) and glomerular (microalbumin) damage [13]. 137 
d)  Outcomes measures 138 
Primary outcomes were evidence of renal damage 24 hours after SWL: 1) incidence 139 
of renal hematomas in routine sonography, and 2) elevated levels of β2-microglobulin 140 
and microalbumin in urine. Secondary outcomes were evidence of clinical 141 
effectiveness: 1) degree of stone disintegration 3 months after SWL, 2) stone-free 142 
rates 3 months after SWL, 3) number of secondary interventions (including re-SWL, 143 
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JJ stent placement, percutaneous nephrolithotomy, and ureteroscopy), and 4) 144 
complications other than hematomas (e.g. urinary tract infections, renal colic, or 145 
steinstrasse) within 3 months of SWL. The severity of complications was graded 146 
according to the Dindo-Clavien classification. Stone composition was documented if 147 
available. 148 
e) Statistical analysis 149 
SAS 9.1 statistical software (SAS Institute Inc., Cary, North Carolina) was used for 150 
statistical analyses. Based on the assumption that the incidence of renal hematomas 151 
is 5 % [6] after treatment with fixed maximal voltage and 0.45 % after treatment with 152 
voltage ramping and that the drop-out rate is 7% [6], a sample size of 428 patients 153 
was required to gain a statistical power of 80% (β=0.2) using a two-sided test at the 154 
significance level of 5% (α=0.05). Clinical outcomes were compared using the chi-155 
square test, Fischer’s exact test, the Student’s t-test, or the Mann-Whitney U-test, as 156 
appropriate. Adjusted odds ratio (OR) and 95% confidence intervals (CI) were 157 
calculated in univariate and multivariate logistic regression model to test for the effect 158 
the mode of voltage application had on the risk of renal hematomas, adjusting for age 159 
(<40 yrs, 40-59 yrs, 50-59 yrs, 60-69 yrs, >70 yrs), female gender, body mass index 160 
(BMI; continuous), and number of SWs (continuous). A two-sided p value <0.05 was 161 






Patient and stone characteristics are shown in Table 1. Of note, the proportions of 166 
stones located in the lower calyx, which usually exhibit lower clearance rates [14], 167 
were comparable between the two groups. Furthermore, the mean number of shock 168 
waves (SW), mean SW frequency, and mean total voltage applied per patient did not 169 
differ between the two groups (p=0.3, 0.4 and 0.1, respectively). 170 
Twenty-four hours after SWL significantly fewer renal hematomas were noted in the 171 
“ramping” group than in the “fixed” group (12/213 [5.6%] vs 27/205 [13%] (difference, 172 
7.5 percentage points, 95%CI, 1.9 to 13; p=0.008;). All patients with renal 173 
hematomas remained hemodynamically stable and were managed conservatively; 174 
none of them required blood transfusions. While mean urinary β2-microglobulin 175 
levels 24 hours after SWL were significantly higher in the “fixed” group than in the 176 
“ramping” group, there was no significant difference in post-SWL urinary 177 
microalbumin levels between the 2 groups (Figure 2). Stone-free rates at 3 months 178 
(146/198 [74%] “fixed” group vs 148/196 [76%] “ramping” group, difference, 1.8 179 
percentage points, 95%CI, - 6.8 to 10; p=0.7), stone disintegration, rates of 180 
secondary interventions, and complications other than hematomas did not 181 
significantly differ between the two groups (Table 2).  182 
Univariate analysis showed higher risk for renal hematomas in patients aged ≥70 yrs 183 
(OR=0.15 [95%CI: 0.04-0.64], p=0.03) and in patients with BMI >30 kg/m² (OR=0.25 184 
[95%CI: 0.10-0.63]; p=0.003) (Figures 3A and 3B). In multivariable analysis, the 185 
mode of energy application was the only variable associated with the risk of renal 186 
hematomas, which was lower with step-wise ramping (OR=0.37 [95%CI 0.18-0.77), 187 
p=0.008) (Table 3). Of note, total energy applied to patients with and without renal 188 
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hematoma did not differ within the two groups (40’995kV vs 40’412kV [p=0.6] in the 189 
“ramping” group and 42’036kV vs 41’582kV [p>0.9] in the “fixed” group). 190 
Stone analysis was available in 114/213 (54%) patients in the “ramping” group and in 191 
110/205 (54%) patients in the “fixed” group. There was no significant difference in 192 






Since the advent of new-generation lithotripters, the increase in the frequency of 197 
renal hematomas associated with their use, most likely due to smaller focal zones 198 
and higher peak pressures, has raised concerns among the urological community 199 
[15]. Although rarely symptomatic, renal hematomas may have devastating long-term 200 
effects [8]. Optimization of energy protocols, therefore, is an area of active research.8 201 
The present study, representing the largest prospective, randomized clinical trial 202 
investigating the effect of the mode of voltage application, demonstrates a beneficial 203 
effect of voltage ramping on renal damage without compromising clinical 204 
effectiveness. 205 
Lambert et al previously published a randomized trial comparing voltage ramping and 206 
fixed energy during SWL [11]. Although urinary markers for renal damage were 207 
routinely collected, the study design did not determine renal hematomas as an 208 
outcome and therefore the investigators did not systemically search for them. 209 
Moreover, the trial had only 45 patients. Nevertheless, significant changes in 210 
microalbumin and β2-microglobulin levels were documented one week after SWL, 211 
suggesting less renal damage with voltage ramping. No changes, however, were 212 
seen 24 hours after SWL. These results contrast with our own, as we found that β2-213 
microglobulin levels (as a marker for tubular damage [13]), but not those of 214 
microalbumin (as a marker for glomerular damage [13]), were significantly higher in 215 
the “fixed” group 24 hours after SWL. Under the hypothesis that one day may not be 216 
enough time for urinary markers of renal damage to be sufficiently expressed in 217 
urine, we cannot exclude that higher levels of both urinary β2-microglobulin and 218 
microalbumin would have been detected at a later time point in the “fixed” group as 219 
shown by Lambert et al [11]. However, others could demonstrate that 220 
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microalbumin and β2-microglobulin were increased 24 hrs after SWL [13, 15, 221 
16]. It could therefore be concluded that power ramping may have a greater 222 
protective effect on renal tubules than on glomerules. 223 
The kinetic energy carried by SWs fragment stones mainly through tear and shear 224 
forces and cavitation, but they also affect the surrounding renal parenchyma [17]. 225 
This may cause tearing of vessels, resulting in subcapsular or perirenal hematoma 226 
[17].Importantly, renal hematomas may lead to parenchymal fibrosis and subsequent 227 
functional loss analogous to that produced by blunt renal trauma [8,18]. The 228 
mechanisms underlying the protective effect of step-wise voltage ramping are not 229 
fully understood. Willis et al demonstrated that low-energy pretreatment of porcine 230 
kidneys significantly reduced the size of renal hemorrhagic lesions compared to no 231 
pretreatment. The authors hypothesized that low-energy SWs induce some degree of 232 
renal vasoconstriction, rendering vessels stiffer and less susceptible to rupture during 233 
the application of higher voltages [9]. This hypothesis was later corroborated by 234 
studies from the same group demonstrating that pretreatment with low-energy SWs 235 
induces early renal vasoconstriction during the application of high-energy SWs. By 236 
contrast, vasoconstriction occurred only after SWL if pretreatment was absent [19]. 237 
Nevertheless, effectors causing vasoconstriction during SWL are unknown and 238 
further research is needed to elucidate the full mechanism behind the renal protective 239 
response seen during voltage ramping.  240 
We found that age ≥70 yrs constitutes a risk factor for renal hematoma, which agrees 241 
with previous data from Dhar et al showing a 1.67-fold increase in the risk of renal 242 
hematomas using the MODULITH® SLX (Storz) for each 10-year incremental 243 
increase in age [20]. Possible reasons for their findings and ours could be increased 244 
capillary fragility associated with age and other uncontrolled factors such as intake of 245 
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drugs affecting hemostasis (e.g. selective serotonin re-uptake inhibitors) or 246 
underlying medical comorbidity. In our study patients with BMI >30 kg/m2 suffered 247 
renal hematomas more frequently after SWL regardless of SW mode, which was 248 
already shown in a recently published retrospective study of 10,887 SWL treatment 249 
sessions on 6177 patients [21]. Obesity is a state of chronic systemic inflammation 250 
and is characterized by oxidative stress that enhances the vulnerability of the 251 
vascular basement membrane which in turn may increase the risk of bleeding during 252 
SWL [22,23]. In view of the above findings, we argue that in patients with advanced 253 
age and/or high BMI, caution should be exercised during SWL and concomitant 254 
treatment of both kidneys should be avoided. 255 
In terms of clinical effectiveness, step-wise voltage ramping performed as well as 256 
fixed maximal voltage. In vitro and in vivo studies have suggested that a progressive 257 
increase in voltage during SWL produces greater stone comminution, mainly by 258 
maintaining favorable stress wave and cavitation bubble dynamics that lead to 259 
constant fragmentation rates [24,25]. In the aforementioned study of Lambert et al, 260 
the “ramping” group achieved stone-free rates of 81% (18/22) versus 48% (11/23) in 261 
the “fixed” group [11]. The definition of “stone-free" was less stringent than in the 262 
present study, as patients with fragments <2mm after a single SWL session were 263 
also deemed stone-free. In another small randomized trial, Demerci et al reported 264 
similar stone-free rates for voltage ramping and fixed voltage [10]. Unfortunately, 265 
those two studies recruited insufficient numbers of patients for definitive conclusions. 266 
Moreover, in the study of Demerci et al, patients underwent multiple SWL sessions 267 
without this confounding factor being taken into account. Interestingly, Honey et al, 268 
comparing immediate versus delayed voltage escalation in 160 patients, showed 269 
lower success rates (defined as sand or fragments ≤4mm) for the latter method 270 
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[12].Reasons for this finding, which conflicts with those of other studies, are unclear 271 
but they could be related to differences in stone burden, stone composition and 272 
location, level of operator experience, ramping protocol, and the type of lithotripter 273 
used. Overall, the discrepancy between our study and other studies may be 274 
explained by differing definitions of success and differences in sample size. Although 275 
well-powered, our study design did not define criteria for clinical effectiveness as a 276 
primary outcome, and given the experimental and theoretical background, superior 277 
clinical effectiveness for step-wise voltage ramping seems to be plausible.  278 
Our prospective, randomized trial is not without limitations. Renal hematomas were 279 
systemically diagnosed by ultrasonography, which may have lower sensitivity and 280 
specificity in the diagnosis of renal hematomas than magnetic resonance imaging 281 
(MRI) or computed tomography (CT) showing an incidence of renal hematomas after 282 
SWL of 15-24% [26-28]. Still, ultrasonography remains an easily accessible and cost-283 
effective imaging modality. Furthermore, the clinical relevance of very small 284 
hematomas not seen with ultrasound but only with MRI or CT is questionable.  285 
Another limitation of our study is that the number of total SWs administered at 286 
maximal energy (18 kV) was higher in the “fixed” group than in the “ramping” group. It 287 
has been shown that renal injury and impairment is greater at higher SW voltages 288 
[17]. There was, however, no significant difference in total energy applied per 289 
kidney/patient between the two groups. Furthermore, total energy applied to patients 290 
with and without post-SWL hematoma did not differ within the two groups. We 291 
therefore attribute the protective effect on the kidney to the voltage ramping strategy.292 
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Conclusion  293 
Step-wise voltage ramping during SWL was associated with a lower risk of renal 294 
damage compared to fixed maximal voltage SWL without compromising treatment 295 
efficacy. Although the optimal ramping-up strategy is not yet defined for each of the 296 
lithotripters currently in use, patients with advanced age (≥70 yrs) and obesity are at 297 
increased risk of post-SWL renal damage and are most likely to benefit from a 298 
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